CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer

Man Zhang, Wei Yang, Peng Wang, Yu Deng, Yu-Ting Dong, Fang-Fang Liu, Rui Huang, Peng Zhang, Ya-Qi Duan, Xin-Dong Liu, Dandan Lin (), Qian Chu () and Bo Zhong ()
Additional contact information
Man Zhang: Medical Research Institute, Zhongnan Hospital of Wuhan University
Wei Yang: Medical Research Institute, Zhongnan Hospital of Wuhan University
Peng Wang: Medical Research Institute, Zhongnan Hospital of Wuhan University
Yu Deng: Tongji Medical College, Huazhong University of Science and Technology
Yu-Ting Dong: Huazhong University of Science and Technology
Fang-Fang Liu: Tongji Medical College, Huazhong University of Science and Technology
Rui Huang: Third Military Medical University (Army Medical University)
Peng Zhang: Tongji Medical College, Huazhong University of Science and Technology
Ya-Qi Duan: Huazhong University of Science and Technology
Xin-Dong Liu: Third Military Medical University (Army Medical University)
Dandan Lin: Cancer Center, Renmin Hospital of Wuhan University
Qian Chu: Tongji Medical College, Huazhong University of Science and Technology
Bo Zhong: Medical Research Institute, Zhongnan Hospital of Wuhan University

Nature Communications, 2020, vol. 11, issue 1, 1-17

Abstract: Abstract The efficacy of checkpoint immunotherapy to non-small cell lung cancer (NSCLC) largely depends on the tumor microenvironment (TME). Here, we demonstrate that CCL7 facilitates anti-PD-1 therapy for the KrasLSL−G12D/+Tp53fl/fl (KP) and the KrasLSL−G12D/+Lkb1fl/fl (KL) NSCLC mouse models by recruiting conventional DC 1 (cDC1) into the TME to promote T cell expansion. CCL7 exhibits high expression in NSCLC tumor tissues and is positively correlated with the infiltration of cDC1 in the TME and the overall survival of NSCLC patients. CCL7 deficiency impairs the infiltration of cDC1 in the TME and the subsequent expansion of CD8+ and CD4+ T cells in bronchial draining lymph nodes and TME, thereby promoting tumor development in the KP mouse model. Administration of CCL7 into lungs alone or in combination with anti-PD-1 significantly inhibits tumor development and prolongs the survival of KP and KL mice. These findings suggest that CCL7 potentially serves as a biomarker and adjuvant for checkpoint immunotherapy of NSCLC.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-19973-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19973-6

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-19973-6

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().